CytomX Therapeutics, Inc. (NASDAQ:CTMX) Short Interest Update

CytomX Therapeutics, Inc. (NASDAQ:CTMX) was the target of a significant drop in short interest in March. As of March 31st, there was short interest totalling 3,320,000 shares, a drop of 5.9% from the March 15th total of 3,530,000 shares. Based on an average daily trading volume, of 864,800 shares, the days-to-cover ratio is presently 3.8 days.

CytomX Therapeutics Stock Performance

NASDAQ CTMX traded down $0.11 during trading on Tuesday, reaching $1.86. 335,827 shares of the company traded hands, compared to its average volume of 871,778. The stock’s 50 day moving average price is $2.02 and its two-hundred day moving average price is $1.62. The company has a market cap of $125.98 million, a price-to-earnings ratio of -96.45 and a beta of 1.01. CytomX Therapeutics has a 1-year low of $1.04 and a 1-year high of $2.86.

CytomX Therapeutics (NASDAQ:CTMX) last posted its earnings results on Monday, March 11th. The biotechnology company reported $0.01 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.02 by ($0.01). The firm had revenue of $26.61 million for the quarter, compared to the consensus estimate of $23.36 million. Equities research analysts expect that CytomX Therapeutics will post -0.21 EPS for the current fiscal year.

Insider Buying and Selling

In related news, CEO Sean A. Mccarthy sold 20,223 shares of CytomX Therapeutics stock in a transaction dated Tuesday, March 19th. The stock was sold at an average price of $2.09, for a total transaction of $42,266.07. Following the sale, the chief executive officer now directly owns 524,481 shares of the company’s stock, valued at $1,096,165.29. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Insiders have sold a total of 35,024 shares of company stock valued at $73,200 over the last three months. 7.00% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

A number of institutional investors have recently modified their holdings of CTMX. UBS Group AG raised its stake in shares of CytomX Therapeutics by 322.8% in the third quarter. UBS Group AG now owns 17,793 shares of the biotechnology company’s stock valued at $26,000 after acquiring an additional 13,585 shares during the last quarter. Cetera Investment Advisers bought a new position in CytomX Therapeutics in the 4th quarter worth approximately $32,000. BNP Paribas Arbitrage SA raised its position in CytomX Therapeutics by 254.2% in the 2nd quarter. BNP Paribas Arbitrage SA now owns 19,318 shares of the biotechnology company’s stock worth $35,000 after purchasing an additional 13,864 shares during the last quarter. Mackenzie Financial Corp bought a new position in CytomX Therapeutics in the 1st quarter worth approximately $35,000. Finally, AlphaMark Advisors LLC raised its position in CytomX Therapeutics by 119.8% in the 4th quarter. AlphaMark Advisors LLC now owns 23,183 shares of the biotechnology company’s stock worth $36,000 after purchasing an additional 12,635 shares during the last quarter. Institutional investors own 67.77% of the company’s stock.

CytomX Therapeutics Company Profile

CytomX Therapeutics, Inc, an oncology-focused biopharmaceutical company, focuses on developing novel conditionally activated biologics localized to the tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclinical research in areas outside of oncology.